Grail shares plunged over 45% after NHS revealed its Galleri multi-cancer blood test missed the trial's primary endpoint.
Longevity News
Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service t...
Source: FierceBiotech - All • Published: 20 Feb 2026, 23:17
Continue exploring
Related longevity signals
Longevity TechnologyInsilico revenue surges 287% in H1 2026 driven by major pharma dealsInsilico’s interim results story — a news article looking at a biotech AI company's recent financial jump and deal-driven momentum, useful for investors and industry watchers.PR NewswireSphingoTec to Engage with Clinical and Industry Partners at Major 2026 ConferencesPreview of a biomarker developer’s planned conference program highlighting presentations and partner engagements across diagnostics and critical care events.Nature - MainWill the mRNA flu shot work better than a regular seasonal one? What the science saysAn analysis of Moderna's newly approved mRNA influenza vaccine and the evidence on its efficacy, safety, and reformulation advantages for seasonal flu control.Longevity TechnologyInsilico Medicine nominates AI-designed drug candidate for major eye diseasesAn article about an AI-designed small-molecule drug candidate for several eye disorders, explaining the discovery approach and preclinical development path.